Jeff Yass’s Pyxis Oncology PYXS Stock Holding History

Jeff Yass’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$56.9K	Buy	+18,900	New	+$36.1K	﹤0.01%	12780
2024 Q4	–	Sell	-11,900	Closed	-$43.7K	–	13014
2024 Q3	$43.7K	Buy	+11,900	New	+$41.6K	﹤0.01%	11430

Other funds holding PYXS

GGI

GordonMD Global Investments Beverely Hills, California $207M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jeff Yass's PYXS Position: Q2 2026 in Review

Jeff Yass sold out of Pyxis Oncology (PYXS) in Q2 2026, closing a stake of 41,201 shares — an estimated $78.8K sold.

Jeff Yass first reported a position in PYXS in Q2 2022 and held it in 13 quarters. The position peaked at $383K in Q2 2024. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

Jeff Yass reported no remaining Pyxis Oncology position as of Q2 2026 after selling out during the quarter.
Jeff Yass sold 41,201 Pyxis Oncology shares in Q2 2026, an estimated $78.8K.
Jeff Yass first reported a position in Pyxis Oncology in Q2 2022 and held it in 13 quarters.
Jeff Yass's Pyxis Oncology position peaked at $383K in Q2 2024.
76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.